Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study

Background: Sorafenib is the currently recommended therapy in patients with advanced hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation of the therapeutic response and prognosis, there is perfusion magnetic resonance imaging (p-MRI) that, through measurement of...

Full description

Saved in:

Bibliographic Details
Published in:	GE Portuguese journal of gastroenterology Vol. 26; no. 4; pp. 260 - 267
Main Authors:	Campos, Marta, Candelária, Isabel, Papanikolaou, Nickolas, Simão, Adélia, Ferreira, Carlos, Manikis, Georgios C., Caseiro-Alves, Filipe
Format:	Journal Article
Language:	English
Published:	Basel, Switzerland S. Karger AG 01-07-2019 Karger Publishers
Subjects:	Angiogenesis Biomarkers Clinical trials Drug dosages Growth factors Hepatocellular carcinoma Inhibitor drugs ktrans Liver cancer Magnetic resonance imaging perfusion Medical prognosis Medical research NMR Nuclear magnetic resonance Original Original Article Patients Sorafenib Targeted cancer therapy Tumor markers Angiogenesis Hepatocellular carcinoma ktrans Tumor markers Magnetic resonance imaging perfusion Sorafenib
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!